Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04530136 · ClinicalTrials.gov registry record · Phase 2
Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
A Phase 2 study, sponsored by Pharming Technologies B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT04530136 is a Phase 2 study that has completed, run by Pharming Technologies B.V.. The registered enrollment target is 38 participants.
The verdict
NCT04530136, a Phase 2 study, has completed, sponsored by Pharming Technologies B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e. ALI requiring mechanical ventilation, or increase the chance of a faster clinical improvement compared to SOC alone.
Interventions
- DRUG Ruconest
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-11-30 |
| Est. Completion | 2021-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04530136
The ClinicalTrials.gov registry entry for NCT04530136 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharming Technologies B.V., which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruconest is the first listed.
NCT04530136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04530136 about?
NCT04530136 is a clinical study titled "Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19". The primary purpose of this study is to evaluate if adding rhC1-INH to standard of care (SOC) in patients admitted for stage II COVID-19 infection may reduce the risk of disease progression, i.e. ALI requiring mechanical ventilation, or increase the chance of a faster clinical improvement compared t...
What is the current status of trial NCT04530136?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2020-11-30. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT04530136?
The interventions under investigation include: Ruconest (DRUG).
Who is sponsoring clinical trial NCT04530136?
This trial is sponsored by Pharming Technologies B.V., which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.